2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: Milan

Poster-Neuroimmunology and disease models

October 25, 2021

Mucosal Associated Invariant T (MAIT) Cells Show Defective Activation in People with Multiple Sclerosis

Background: mucosal associated invariant T (MAIT) cells are innate-like T cells expressing an invariant TCR ? chain with a limited number...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease

Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Eculizumab in Nmosd and MG – Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions

Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...

Read More →

Platform-Neuroimaging

October 25, 2021

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC